Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.

Gao Y, Maria A, Na N, Paula ADC, Gorelick AN, Hechtman JF, Carson J, Lefkowitz RA, Weigelt B, Taylor BS, Zhao H, Reis-Filho JS, de Stanchina E, Rosen N, Yao Z, Yaeger R.

Cancer Discov. 2019 Jun 21. doi: 10.1158/2159-8290.CD-19-0356. [Epub ahead of print]

PMID:
31227518
2.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

3.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
4.

Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.

Cassidy MR, Lefkowitz RA, Long N, Qin LX, Kirane A, Sbaity E, Hameed M, Coit DG, Brennan MF, Singer S, Crago AM.

Ann Surg. 2018 Nov 9. doi: 10.1097/SLA.0000000000003073. [Epub ahead of print]

PMID:
30418203
5.

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD.

Oncologist. 2019 Jun;24(6):857-863. doi: 10.1634/theoncologist.2018-0160. Epub 2018 Aug 20.

PMID:
30126857
6.

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP.

Cancer Immunol Res. 2018 Feb;6(2):189-200. doi: 10.1158/2326-6066.CIR-17-0356. Epub 2018 Jan 16.

7.

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD.

Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306.

8.

Myxoinflammatory Fibroblastic Sarcoma: Clinical, Imaging, Management and Outcome in 29 Patients.

Kumar R, Lefkowitz RA, Neto AD.

J Comput Assist Tomogr. 2017 Jan;41(1):104-115. doi: 10.1097/RCT.0000000000000490.

PMID:
27560024
9.

Infiltrative pattern of carcinomatosis in extremity muscles on MRI.

Soliman F, Hwang S, Landa J, Lefkowitz RA, Panicek DM.

Clin Imaging. 2016 May-Jun;40(3):451-5. doi: 10.1016/j.clinimag.2015.12.012. Epub 2016 Jan 15.

10.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

11.

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD.

Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14.

12.

⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.

13.

Biopsy of suspicious bone lesions in patients with a single known malignancy: prevalence of a second malignancy.

Raphael B, Hwang S, Lefkowitz RA, Landa J, Sohn M, Panicek DM.

AJR Am J Roentgenol. 2013 Dec;201(6):1309-14. doi: 10.2214/AJR.12.10261.

PMID:
24261372
14.

Musculoskeletal tumors and tumor-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part A: benign conditions that may mimic malignancy.

Ulaner G, Hwang S, Lefkowitz RA, Landa J, Panicek DM.

Int Orthop. 2013 May;37(5):871-6. doi: 10.1007/s00264-013-1823-7. Epub 2013 Feb 23. Review.

15.

Musculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumours.

Ulaner G, Hwang S, Landa J, Lefkowitz RA, Panicek DM.

Int Orthop. 2013 May;37(5):877-82. doi: 10.1007/s00264-013-1824-6. Epub 2013 Feb 17. Review.

16.

Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging.

Lefkowitz RA, Landa J, Hwang S, Zabor EC, Moskowitz CS, Agaram NP, Panicek DM.

Skeletal Radiol. 2013 Jun;42(6):809-18. doi: 10.1007/s00256-012-1563-6. Epub 2013 Jan 15.

17.

Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes.

Vargas HA, Chaim J, Lefkowitz RA, Lakhman Y, Zheng J, Moskowitz CS, Sohn MJ, Schwartz LH, Russo P, Akin O.

Radiology. 2012 Sep;264(3):779-88. doi: 10.1148/radiol.12110746. Epub 2012 Jul 24.

PMID:
22829683
18.

Percutaneous CT-guided bone biopsy: diagnosis of malignancy in lesions with initially indeterminate biopsy results and CT features associated with diagnostic or indeterminate results.

Hwang S, Lefkowitz RA, Landa J, Zheng J, Moskowitz CS, Maybody M, Hameed M, Panicek DM.

AJR Am J Roentgenol. 2011 Dec;197(6):1417-25. doi: 10.2214/AJR.11.6820.

PMID:
22109298
19.

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, Guo P, Kris MG, Schwartz LH, Riely GJ.

J Clin Oncol. 2011 Aug 10;29(23):3114-9. doi: 10.1200/JCO.2010.33.7071. Epub 2011 Jul 5.

20.

Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG.

Clin Cancer Res. 2011 Jun 15;17(12):4082-90. doi: 10.1158/1078-0432.CCR-10-3322. Epub 2011 Mar 29.

21.

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP.

J Clin Oncol. 2011 Mar 1;29(7):868-74. doi: 10.1200/JCO.2010.32.0770. Epub 2010 Dec 28.

22.

Imaging characteristics of primary osteosarcoma: nonconventional subtypes.

Yarmish G, Klein MJ, Landa J, Lefkowitz RA, Hwang S.

Radiographics. 2010 Oct;30(6):1653-72. doi: 10.1148/rg.306105524. Review.

PMID:
21071381
23.

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.

Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1113-21. doi: 10.1007/s00280-010-1269-1. Epub 2010 Feb 21.

24.

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK.

Invest New Drugs. 2011 Oct;29(5):1004-12. doi: 10.1007/s10637-010-9447-x. Epub 2010 May 12.

25.

Imaging findings, prevalence and outcome of de novo and secondary malignant fibrous histiocytoma of bone.

Koplas MC, Lefkowitz RA, Bauer TW, Joyce MJ, Ilaslan H, Landa J, Sundaram M.

Skeletal Radiol. 2010 Aug;39(8):791-8. doi: 10.1007/s00256-009-0822-7. Epub 2009 Nov 20.

PMID:
19936744
26.

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, Qin Y, Riely GJ, Kris MG, Schwartz LH.

Radiology. 2009 Jul;252(1):263-72. doi: 10.1148/radiol.2522081593.

27.

A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly EM.

Pancreatology. 2009;9(4):404-9. doi: 10.1159/000187135. Epub 2009 May 19.

28.

Significance of peritumoral vascularity on CT in evaluation of renal cortical tumor.

Zhang J, Lefkowitz RA, Wang L, Ishill NM, Moskowitz CS, Russo P, Hricak H.

J Comput Assist Tomogr. 2007 Sep-Oct;31(5):717-23.

PMID:
17895782
29.

Solid renal cortical tumors: differentiation with CT.

Zhang J, Lefkowitz RA, Ishill NM, Wang L, Moskowitz CS, Russo P, Eisenberg H, Hricak H.

Radiology. 2007 Aug;244(2):494-504.

PMID:
17641370
30.

Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease.

Waters B, Panicek DM, Lefkowitz RA, Antonescu CR, Healey JH, Athanasian EA, Brennan MF.

AJR Am J Roentgenol. 2007 Feb;188(2):W193-8.

PMID:
17242227
31.

Imaging of bladder cancer.

Zhang J, Gerst S, Lefkowitz RA, Bach A.

Radiol Clin North Am. 2007 Jan;45(1):183-205. Review.

PMID:
17157629
32.

Imaging of kidney cancer.

Zhang J, Lefkowitz RA, Bach A.

Radiol Clin North Am. 2007 Jan;45(1):119-47. Review.

PMID:
17157626
33.

Breath-hold magnetic resonance cholangiopancreatography in the evaluation of malignant pancreaticobiliary obstruction.

Schwartz LH, Lefkowitz RA, Panicek DM, Coakley FV, Jarnagin W, Dematteo R, Fong Y, Blumgart L.

J Comput Assist Tomogr. 2003 May-Jun;27(3):307-14.

PMID:
12794591
34.

Routine editing of trainee-generated radiology reports: effect on style quality.

Coakley FV, Heinze SB, Shadbolt CL, Schwartz LH, Ginsberg MS, Lefkowitz RA, Hilton S, Conlon K, Leibel S, Tumbull A, Panicek DM.

Acad Radiol. 2003 Mar;10(3):289-94.

PMID:
12643556
36.

Left-sided omental infarction with associated omental abscess: CT diagnosis.

Balthazar EJ, Lefkowitz RA.

J Comput Assist Tomogr. 1993 May-Jun;17(3):379-81.

PMID:
8491897

Supplemental Content

Loading ...
Support Center